Eli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea

Key TakeawaysEli Lilly on Wednesday said its weight-loss treatment, Zepbound, was successful in helping patients with obstructive sleep apnea (OSA).A Phase 3 trial found on average Zepbound reduced the number of sleep-apnea events by up to 63%.The drug maker plans to ask the Food and Drug Administration (FDA) and other regulators to expand the use of Zepbound for OSA by mid-year. Shares of Eli Lilly (LLY) gained in intraday trading Wednesday after the pharmaceutical firm said a late-stage study found its we ...